DK3124483T3 - Pyrazolaminopyrimidin-derivater som LRRK2-modulatorer - Google Patents

Pyrazolaminopyrimidin-derivater som LRRK2-modulatorer Download PDF

Info

Publication number
DK3124483T3
DK3124483T3 DK16180927.2T DK16180927T DK3124483T3 DK 3124483 T3 DK3124483 T3 DK 3124483T3 DK 16180927 T DK16180927 T DK 16180927T DK 3124483 T3 DK3124483 T3 DK 3124483T3
Authority
DK
Denmark
Prior art keywords
pyrazolaminopyrimidine
derivatives
lrrk2 modulators
lrrk2
modulators
Prior art date
Application number
DK16180927.2T
Other languages
English (en)
Inventor
Charles Baker-Glenn
Daniel Jon Burdick
Mark Chambers
Huifen Chen
Anthony Estrada
Zachary Kevin Sweeney
Bryan K Chan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK3124483T3 publication Critical patent/DK3124483T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
DK16180927.2T 2010-11-10 2011-11-09 Pyrazolaminopyrimidin-derivater som LRRK2-modulatorer DK3124483T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41227310P 2010-11-10 2010-11-10
US201161546613P 2011-10-13 2011-10-13
EP11782588.5A EP2638031B9 (en) 2010-11-10 2011-11-09 Pyrazole aminopyrimidine derivatives as lrrk2 modulators

Publications (1)

Publication Number Publication Date
DK3124483T3 true DK3124483T3 (da) 2019-09-02

Family

ID=44983512

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11782588.5T DK2638031T3 (da) 2010-11-10 2011-11-09 Pyrazolaminopyrimidinderivater som lrrk2-modulatorer
DK16180927.2T DK3124483T3 (da) 2010-11-10 2011-11-09 Pyrazolaminopyrimidin-derivater som LRRK2-modulatorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11782588.5T DK2638031T3 (da) 2010-11-10 2011-11-09 Pyrazolaminopyrimidinderivater som lrrk2-modulatorer

Country Status (28)

Country Link
US (1) US8815882B2 (da)
EP (3) EP2638031B9 (da)
JP (3) JP5986094B2 (da)
KR (1) KR101566091B1 (da)
CN (1) CN103313978B (da)
AR (1) AR083813A1 (da)
AU (1) AU2011328139A1 (da)
BR (1) BR112013011600B1 (da)
CA (2) CA2812669C (da)
CY (1) CY1120073T1 (da)
DK (2) DK2638031T3 (da)
EC (1) ECSP13012611A (da)
ES (2) ES2746134T3 (da)
HK (1) HK1187605A1 (da)
HR (2) HRP20172006T1 (da)
HU (2) HUE037844T2 (da)
IL (1) IL225234A0 (da)
LT (2) LT3124483T (da)
MA (1) MA34644B1 (da)
MX (1) MX2013005199A (da)
NO (1) NO2638031T3 (da)
PL (2) PL3124483T3 (da)
PT (2) PT2638031T (da)
RS (2) RS59106B1 (da)
SG (1) SG189043A1 (da)
SI (2) SI3124483T1 (da)
TW (1) TW201302733A (da)
WO (1) WO2012062783A1 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140041583A (ko) 2011-05-23 2014-04-04 엘란 파마슈티컬스, 엘엘씨 Lrrk2 키나제 활성의 억제제
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
MX349556B (es) 2011-11-29 2017-08-03 Genentech Inc Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
RU2651544C2 (ru) * 2011-11-29 2018-04-20 Дженентек, Инк. Производные аминопиримидина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
PT2785711T (pt) * 2011-11-29 2016-09-30 Hoffmann La Roche Derivados de 2-(fenil ou pirid-3- il)aminopiridinacomo moduladores de lrrk2 quinase, para o tratamento da doença de parkinson
US20140228384A1 (en) * 2011-11-29 2014-08-14 Genentech, Inc. Assays and biomarkers for lrrk2
MX353254B (es) * 2011-11-30 2018-01-05 Genentech Inc Radioligandos marcados con fluor-18 y carbono-11 para la formacion de imagenes por tomografia de emision de positrones para proteina cinasa 2 de repeticion rica en leucina (lrrk2).
JP6218808B2 (ja) * 2012-05-03 2017-10-25 ジェネンテック, インコーポレイテッド Lrrk2モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体
WO2013164323A1 (en) * 2012-05-03 2013-11-07 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
EP2867236B1 (en) 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク LRRK2阻害薬としての新規の3,4−二置換−1H−ピロロ[2,3−b]ピリジンおよび4,5−二置換−7H−ピロロ[2,3−c]ピリダジン
KR102374178B1 (ko) 2013-12-17 2022-03-14 메르크 파텐트 게엠베하 피루베이트 데히드로게나아제 키나아제의 저해제로서의 n1-(3,3,3-트리플루오로-2-히드록소-2-메틸프로피오닐)-피페리딘 유도체
CA2934061A1 (en) 2013-12-20 2015-06-25 Signal Pharmaceuticals, Llc Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
JP6474826B2 (ja) 2014-01-29 2019-02-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 化合物
AU2015210593A1 (en) 2014-01-29 2016-07-07 Glaxosmithkline Intellectual Property Development Limited Compounds
EP3122730B1 (en) * 2014-03-28 2020-03-25 Calitor Sciences, LLC Substituted heteroaryl compounds and methods of use
EP2927221A1 (en) * 2014-03-31 2015-10-07 Commonwealth Scientific and Industrial Research Organisation Diamine compounds for phosphorescent diazaborole metal complexes and electroluminescent devices
JP6637880B2 (ja) 2014-05-08 2020-01-29 東ソー・ファインケム株式会社 5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法
WO2015176010A1 (en) 2014-05-15 2015-11-19 The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services Treatment or prevention of an intestinal disease or disorder
JP6262079B2 (ja) * 2014-06-02 2018-01-17 東ソー・ファインケム株式会社 4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法
JP6431294B2 (ja) * 2014-06-16 2018-11-28 東ソー・ファインケム株式会社 5−(トリフルオロメチル)ピリミジン誘導体及びその製造法
ES2699948T3 (es) 2014-10-14 2019-02-13 Sunshine Lake Pharma Co Ltd Compuestos de heteroarilo sustituido y métodos de uso
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
ES2797301T3 (es) 2016-03-29 2020-12-01 Merck Patent Gmbh Derivados de piperidinil-propanona
EP3448850B1 (en) 2016-04-28 2020-11-04 Merck Patent GmbH Piperidinyl derivatives
WO2017218843A1 (en) * 2016-06-16 2017-12-21 Denali Therapeutics Inc. Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
CN106588884B (zh) * 2016-11-10 2019-04-09 浙江大学 2-多取代芳环-嘧啶类衍生物及制备和医药用途
CN106588885B (zh) * 2016-11-10 2019-03-19 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
WO2018155947A1 (ko) 2017-02-24 2018-08-30 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
US20200157081A1 (en) * 2017-05-24 2020-05-21 Denali Therapeutics Inc. Compounds, compositions and methods
UY37808A (es) * 2017-07-14 2019-02-28 Glaxosmithkline Ip Dev Ltd Nuevos compuestos que inhiben la actividad quinasa de la lrrk2
WO2019099311A1 (en) 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
AR113893A1 (es) * 2017-11-21 2020-06-24 Denali Therapeutics Inc Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción
JP7284172B2 (ja) * 2017-12-20 2023-05-30 デナリ セラピューティクス インコーポレイテッド ピリミジニル-4-アミノピラゾール化合物の調製方法
WO2019160037A1 (ja) * 2018-02-14 2019-08-22 国立大学法人 東京大学 酸ハロゲン化物による化合物の製造方法
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AR118641A1 (es) * 2019-04-11 2021-10-20 Denali Therapeutics Inc Compuestos, composiciones y métodos
EP3975719A4 (en) * 2019-05-31 2023-07-05 Denali Therapeutics Inc. MODIFIED RELEASE FORMULATION OF A PYRIMIDINYLAMINO-PYRAZOLE COMPOUND, AND METHODS OF TREATMENT
CN110627810A (zh) * 2019-06-05 2019-12-31 中国医学科学院药用植物研究所 一种三氟甲基吡唑衍生物的制备方法
WO2021178485A1 (en) * 2020-03-06 2021-09-10 National Health Research Institutes Pyrimidine compounds and their pharmaceutical uses
CA3172750A1 (en) 2020-03-23 2021-09-30 Ge Hyeong Lee Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same
KR102342803B1 (ko) 2020-03-23 2021-12-24 환인제약 주식회사 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
EP4232040A1 (en) 2020-10-20 2023-08-30 F. Hoffmann-La Roche AG Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk﹘5抑制劑和彼之用途
WO2022197577A1 (en) * 2021-03-17 2022-09-22 Merck Sharp & Dohme Llc Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
JP2024511466A (ja) * 2021-03-26 2024-03-13 スミトモ ファーマ オンコロジー, インコーポレイテッド Alk-5阻害剤及びその使用
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2023174946A1 (en) 2022-03-15 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Early and non-invasive method for assessing a subject's risk of having parkinson's disease
WO2023224894A1 (en) * 2022-05-20 2023-11-23 Merck Sharp & Dohme Llc Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0723533A1 (en) 1993-10-12 1996-07-31 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
DE69943247D1 (de) 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
US6172222B1 (en) 1998-06-08 2001-01-09 American Home Products Corporation Diaminopyrazoles
US6458823B1 (en) 1998-06-08 2002-10-01 Wyeth Diaminopyrazoles
NZ511116A (en) 1998-11-10 2003-08-29 Janssen Pharmaceutica Nv HIV replication inhibiting pyrimidines
KR20020030791A (ko) 1999-08-12 2002-04-25 버텍스 파마슈티칼스 인코포레이티드 c-JUN N-말단 키나제(JNK) 및 기타의 단백질키나제 억제제
EA005423B1 (ru) 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Противовирусные композиции
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
CA2406562C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001292670A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4377583B2 (ja) 2000-12-05 2009-12-02 バーテックス ファーマシューティカルズ インコーポレイテッド C−junn末端キナーゼ(jnk)および他のタンパク質キナーゼのインヒビター
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
MXPA03005606A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
CZ304059B6 (cs) 2000-12-21 2013-09-11 Glaxo Group Limited Deriváty pyrimidinu a farmaceutický prostredek
CA2446864C (en) 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
MXPA03010810A (es) 2001-05-29 2004-03-22 Schering Ag Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos.
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US7087614B2 (en) 2001-06-19 2006-08-08 Bristol-Myers Squibb Co. Pyrimidine inhibitors of phosphodiesterase (PDE) 7
EP1408978A4 (en) 2001-06-21 2005-07-13 Ariad Pharma Inc NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
US20030139435A1 (en) 2001-06-26 2003-07-24 Gulzar Ahmed N-heterocyclic inhibitors of TNF-alpha expression
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
WO2003032997A1 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
WO2003055489A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP1483260A1 (de) * 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
CN1717396A (zh) 2002-11-28 2006-01-04 舍林股份公司 Chk-、Pdk-和Akt-抑制嘧啶,其制备及作为药物的用途
WO2004067516A1 (en) 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
AU2004240720A1 (en) 2003-05-21 2004-12-02 Bayer Cropscience Aktiengesellschaft Iodopyrazolyl carboxanilides
CA2531490A1 (en) 2003-07-15 2005-02-03 Neurogen Corporation Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands
JP2007500178A (ja) 2003-07-30 2007-01-11 サイクラセル・リミテッド プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体
ES2421139T3 (es) * 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
DK1663242T3 (da) 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
EP1758887A1 (en) 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
JP4812763B2 (ja) 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ, インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
CA2571937A1 (en) 2004-07-08 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of pkc-theta
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US20060058525A1 (en) 2004-09-01 2006-03-16 Rajinder Singh Synthesis of 2,4-pyrimidinediamine compounds
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
ES2380550T3 (es) 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Compuestos de espiro-2,4-pirimidindiamina y sus usos
EP1828183A1 (en) 2004-12-17 2007-09-05 AstraZeneca AB 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
DE102005008310A1 (de) 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
EP1705177A1 (en) 2005-03-23 2006-09-27 Schering Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
CN101218229A (zh) 2005-05-05 2008-07-09 阿斯利康(瑞典)有限公司 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
AU2006254840B2 (en) 2005-06-08 2012-08-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
NZ564222A (en) 2005-06-14 2011-10-28 Taigen Biotechnology Co Ltd Pyrimidine compounds
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2007030362A1 (en) 2005-09-07 2007-03-15 Laboratoires Serono Sa. Ikk inhibitors for the treatment of endometriosis
US20090149467A1 (en) * 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
PE20080068A1 (es) 2006-05-15 2008-03-17 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
KR20090023698A (ko) 2006-06-15 2009-03-05 베링거 인겔하임 인터내셔날 게엠베하 2-아닐리노-4-아미노알킬렌아미노피리미딘
US20080131937A1 (en) 2006-06-22 2008-06-05 Applera Corporation Conversion of Target Specific Amplification to Universal Sequencing
JP2009545598A (ja) 2006-08-01 2009-12-24 プリーシス・ファーマシューティカルズ・インコーポレイテッド P38キナーゼ阻害剤
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
US20080194575A1 (en) 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
ES2377717T3 (es) 2006-11-27 2012-03-30 Ares Trading S.A. Tratamiento del mieloma múltiple
MX2009006081A (es) 2006-12-08 2009-06-17 Irmc Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
AU2007337088A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Pyrimidine kinase inhibitors
EP1939185A1 (de) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
US20100144706A1 (en) 2006-12-22 2010-06-10 Boehringer Ingelheim International Gmbh Compounds
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Adおよび関連状態の治療のためのピペラジン誘導体
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
UY31048A1 (es) 2007-04-25 2008-11-28 Astrazeneca Ab Nuevos compuestos de pirimidina y usos de los mismos
MX2009013262A (es) 2007-06-08 2010-01-25 Bayer Cropscience Sa Derivados de heterociclil-pirimidinil-amino fungicidas.
WO2009012421A1 (en) 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
CN101878216B (zh) 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
US8058279B2 (en) 2007-10-09 2011-11-15 Dow Agrosciences Llc Insecticidal pyrimidinyl aryl hyrdrazones
EP2220068B1 (en) 2007-11-16 2016-01-27 Incyte Holdings Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
US8461147B2 (en) 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
BRPI0821151A2 (pt) 2007-12-07 2015-06-16 Novartis Ag Derivados de pirazol e uso dos mesmos como inibidores de quinases dependentes de ciclina
EP2265607B1 (en) 2008-02-15 2016-12-14 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
US20100056524A1 (en) 2008-04-02 2010-03-04 Mciver Edward Giles Compound
WO2009127642A2 (en) * 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
LT2300013T (lt) 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Fosforo dariniai kaip kinazių inhibitoriai
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
EP2303824B1 (en) 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2011529920A (ja) 2008-07-31 2011-12-15 ジェネンテック, インコーポレイテッド ピリミジン化合物、組成物及び使用方法
WO2010024430A1 (ja) 2008-09-01 2010-03-04 アステラス製薬株式会社 2,4-ジアミノピリミジン化合物
US20110245242A1 (en) 2008-09-03 2011-10-06 Bayer Cropscience Ag Heterocyclically Substituted Anilinopyrimides
US20100144722A1 (en) 2008-09-03 2010-06-10 Dr. Reddy's Laboratories Ltd. Novel heterocyclic compounds as gata modulators
WO2010025863A2 (de) 2008-09-03 2010-03-11 Bayer Cropscience Ag 4-alkyl-substituierte diaminopyrimidine
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
EA201100434A1 (ru) 2008-09-03 2011-10-31 Байер Кропсайенс Аг Гетероциклически замещенные анилинопиримидины в качестве фунгицидов
WO2010038081A2 (en) 2008-10-03 2010-04-08 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
JP5908728B2 (ja) 2009-01-06 2016-04-26 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
US20110071158A1 (en) 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
EP2415765A4 (en) * 2009-03-30 2012-08-15 Astellas Pharma Inc PYRIMIDINE COMPOUND
EP2419423A1 (en) 2009-04-14 2012-02-22 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CA2763717A1 (en) 2009-06-10 2010-12-16 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors
CA2764983A1 (en) * 2009-06-10 2010-12-16 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
WO2010146132A1 (en) 2009-06-18 2010-12-23 Cellzome Limited Sulfonamides and sulfamides as zap-70 inhibitors
CA2763730A1 (en) 2009-06-18 2010-12-23 Cellzome Limited Heterocyclylaminopyrimidines as kinase inhibitors
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
AU2010302842B2 (en) 2009-09-29 2014-05-08 Glaxo Group Limited Novel compounds
MX2012005332A (es) 2009-11-13 2012-10-15 Oscotec Inc Inhibidores de cinasa.
CN105693861A (zh) 2009-12-29 2016-06-22 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
US8470820B2 (en) 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
MX2012014158A (es) * 2010-06-04 2013-02-07 Hoffmann La Roche Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
MX349556B (es) * 2011-11-29 2017-08-03 Genentech Inc Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
AR089182A1 (es) * 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
PT2785711T (pt) * 2011-11-29 2016-09-30 Hoffmann La Roche Derivados de 2-(fenil ou pirid-3- il)aminopiridinacomo moduladores de lrrk2 quinase, para o tratamento da doença de parkinson
RU2651544C2 (ru) * 2011-11-29 2018-04-20 Дженентек, Инк. Производные аминопиримидина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
MX353254B (es) * 2011-11-30 2018-01-05 Genentech Inc Radioligandos marcados con fluor-18 y carbono-11 para la formacion de imagenes por tomografia de emision de positrones para proteina cinasa 2 de repeticion rica en leucina (lrrk2).

Also Published As

Publication number Publication date
ES2653967T3 (es) 2018-02-09
RS59106B1 (sr) 2019-09-30
MX2013005199A (es) 2013-06-28
HUE046617T2 (hu) 2020-03-30
LT3124483T (lt) 2019-09-25
EP2638031A1 (en) 2013-09-18
PT3124483T (pt) 2019-10-02
EP3124483A1 (en) 2017-02-01
JP6524284B2 (ja) 2019-06-05
PL3124483T3 (pl) 2020-03-31
RS56583B1 (sr) 2018-02-28
JP5986094B2 (ja) 2016-09-06
BR112013011600B1 (pt) 2022-01-11
HRP20172006T1 (hr) 2018-02-09
EP3124483B1 (en) 2019-07-10
PL2638031T3 (pl) 2018-03-30
IL225234A0 (en) 2013-06-27
CN103313978A (zh) 2013-09-18
CA3017869C (en) 2021-07-27
KR101566091B1 (ko) 2015-11-04
NO2638031T3 (da) 2018-03-10
HUE037844T2 (hu) 2018-09-28
SG189043A1 (en) 2013-05-31
CA3017869A1 (en) 2012-05-18
EP2638031B1 (en) 2017-10-11
SI3124483T1 (sl) 2019-10-30
HK1187605A1 (en) 2014-04-11
BR112013011600A8 (pt) 2021-09-08
AU2011328139A1 (en) 2013-04-04
SI2638031T1 (en) 2018-02-28
CN103313978B (zh) 2015-04-15
AR083813A1 (es) 2013-03-27
KR20130093657A (ko) 2013-08-22
US20120157427A1 (en) 2012-06-21
ECSP13012611A (es) 2013-07-31
LT2638031T (lt) 2017-12-11
CY1120073T1 (el) 2018-12-12
US8815882B2 (en) 2014-08-26
ES2746134T3 (es) 2020-03-04
JP2018109038A (ja) 2018-07-12
TW201302733A (zh) 2013-01-16
HRP20191781T1 (hr) 2019-12-27
DK2638031T3 (da) 2017-12-11
PT2638031T (pt) 2018-01-03
MA34644B1 (fr) 2013-11-02
CA2812669C (en) 2018-11-06
JP6298115B2 (ja) 2018-03-20
EP2638031B9 (en) 2020-01-08
JP2017008074A (ja) 2017-01-12
JP2013545741A (ja) 2013-12-26
BR112013011600A2 (pt) 2016-08-09
WO2012062783A1 (en) 2012-05-18
CA2812669A1 (en) 2012-05-18
EP3590933A1 (en) 2020-01-08
EP3590933B1 (en) 2021-01-06

Similar Documents

Publication Publication Date Title
DK3124483T3 (da) Pyrazolaminopyrimidin-derivater som LRRK2-modulatorer
HRP20160771T1 (hr) Derivati aminopirimidina kao modulatori za lrrk2
DK2411393T3 (da) Kondenserede pyrimidin-dionderivater som TRPA1-modulatorer
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
DK2590974T3 (da) Tetrahydropyridopyrimidinderivater
DK2616102T3 (da) Prodrugs, som omfatter et exendin-linker-konjugat
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
DK3103797T3 (da) 2,5-dioxoimidazolidin-1-yl-3-phenylurinstofderivater som formylpeptidreceptor-lignende-1- (fprl-1) receptormodulatorer
DK2411397T3 (da) Isothiazol-pyrimidindionderivater som modulatorer af TRPA1
DK2678329T3 (da) Triazolopyridinforbindelser som pim-kinase-hæmmere
DK3070091T3 (da) Benzodioxolderivater som phosphodiesterasehæmmere
DK2513105T3 (da) 2-arylimidazolderivater som pde10a-enzyminhibitorer
DK2938615T3 (da) Imidazopyridazin-derivater som GABAA-receptormodulatorer
DK2513106T3 (da) Heteroaromatiske aryltriazol-derivater som pde10a-enzyminhibitorer
DE102011075103A8 (de) Photodetektor
BR112014000015A2 (pt) formulação
DK2252609T3 (da) Pyridin-2-yl-derivater som immunomodulerende midler
UA21334S (uk) Цукерка
CO6960557A2 (es) Derivados de 2-yodo-imidazol
BR112013013837A2 (pt) derivados de substituição de imidazoquinolina
DK2635269T3 (da) Kombinationspræparat
DK2609083T3 (da) Substituerede 2-oxy-quinolin-3-carboxamider som KCNQ2/3 modulatorer
DK2655518T3 (da) Dispersions-azo-farvestoffer
SMT201500067B (it) Derivati di acilbenzene
DK2367787T3 (da) 3-phenyl-3-methoxypyrrolidinderivater som modulatorer af kortikal katekolaminerg neurotransmission